サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1298765

抗結核薬市場：疾患タイプ、診断・治療、エンドユーザー、地域別2023-2028年

Anti-Tuberculosis Therapeutics Market by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 139 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗結核薬市場：疾患タイプ、診断・治療、エンドユーザー、地域別2023-2028年
出版日: 2023年06月14日
発行: IMARC
ページ情報: 英文 139 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗結核薬市場規模は2022年に13億5,479万米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて6.70%の成長率（CAGR）を示し、2028年までに19億9,134万米ドルに達すると予測しています。ヘルスケア支出の増加、有利な償還政策、技術の進歩、官民パートナーシップの拡大などが市場を牽引する主な要因です。

抗結核薬は、結核菌によって引き起こされる細菌感染症である結核を管理するために使用される薬剤および治療戦略を指します。結核は主に肺に感染し、腎臓、脊椎、脳など体の他の部位にも広がる可能性があります。抗結核薬は、結核菌を体内から根絶し、感染の拡大を防ぐために使用されます。これは、通常6～9ヵ月間処方される抗生物質の組み合わせによって達成されます。最も一般的に使用される薬剤には、イソニアジド、リファンピン、エタンブトール、ピラジナミドなどがあります。使用する薬剤の正確な組み合わせは、感染の重症度や患者の健康状態によって異なります。さらに、治療の成功と薬剤耐性結核の発生を防ぐためには、定期的なモニタリングと経過観察も不可欠です。近年、抗結核薬は、酸素療法、栄養サポート、起こりうる合併症の管理などの支持療法も含むため、支持を集めています。

抗結核薬市場の動向：

市場を牽引する主な要因の1つは、世界的に、特に低・中所得国で結核の有病率が高いことです。加えて、不完全な治療、不十分なヘルスケアインフラ、適切なヘルスケアへのアクセス不足による薬剤耐性結核の発生率の増加が、市場成長にプラスの影響を与えています。このほか、新薬や治療戦略の開拓も抗結核薬市場を牽引しています。近年、ベダキリンやデラマニドなどの新薬が結核治療薬として承認されました。これらの薬剤は、従来の結核治療薬に比べて有効性と安全性が向上しています。これに伴い、技術や診断の進歩により結核の早期発見・診断が可能となり、タイムリーな治療開始と患者の予後改善につながっています。さらに、特に新興国におけるヘルスケア支出の増加は、ヘルスケアインフラの改善と、結核治療を含む質の高いヘルスケアへのアクセスの向上をもたらしています。これとは別に、結核に対する意識の高まりや早期診断・治療の重要性も、抗結核薬の需要を高めています。さらに、政府の取り組みや結核対策プログラムへの資金援助は、抗結核薬市場の牽引役として重要な役割を果たしています。例えば、政府と非政府組織（NGO）が協力して、認知度の向上、診断の改善、安価で効果的な治療法へのアクセスの確保に取り組んでおり、これが今後数年間の市場成長を促進すると予想されます。

本レポートで扱う主な質問

  • 世界の抗結核薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 世界の抗結核薬市場における市場促進要因、市場抑制要因、機会は何か？
  • 各駆動要因、抑制要因、機会が世界の抗結核薬市場に与える影響は？
  • 主要な地域市場は？
  • 最も魅力的な抗結核薬市場はどの国か？
  • 疾患タイプ別の市場内訳は？
  • 抗結核薬市場で最も魅力的な疾患タイプは？
  • 診断と治療に基づく市場内訳は？
  • 抗結核薬市場で最も魅力的な診断・治療法はどれか？
  • エンドユーザー別の市場内訳は？
  • 抗結核薬市場で最も魅力的なエンドユーザーはどこか？
  • 世界の抗結核薬市場の競合構造は？
  • 世界の抗結核薬市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 抗結核薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：疾患タイプ別

  • 活動性結核
    • 市場動向
    • 市場予測
  • 潜在性結核
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：診断・治療別

  • 診断
    • 市場動向
    • 主要セグメント
      • 血液検査
      • 画像検査
      • 喀痰検査
      • その他
    • 市場予測
  • 治療
    • 市場動向
    • 主要セグメント
      • ファーストライン治療薬
      • 主要タイプ
      • イソニアジド
      • エタンブトール
      • リファンピン
      • その他
      • 第二選択薬
      • 主な種類
      • チアセタゾン
      • パラアミノサリチル酸（PAS）
      • その他
      • その他
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 専門クリニック
    • 市場動向
    • 市場予測
  • ホームケア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要プレーヤー
  • 主要プレーヤーのプロファイル
    • F. Hoffmann-La Roche Ltd.
    • Lannett Company Inc.
    • Lupin Limited
    • Macleods Pharmaceuticals Limited
    • Otsuka Pharmaceutical Co. Ltd
図表

List of Figures

  • Figure 1: Global: Anti-Tuberculosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017-2022
  • Figure 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 4: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Disease Type (in %), 2022
  • Figure 5: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Diagnosis and Treatment (in %), 2022
  • Figure 6: Global: Anti-Tuberculosis Therapeutics Market: Breakup by End User (in %), 2022
  • Figure 7: Global: Anti-Tuberculosis Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Anti-Tuberculosis Therapeutics (Active TB) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Anti-Tuberculosis Therapeutics (Active TB) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Anti-Tuberculosis Therapeutics (Latent TB) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Anti-Tuberculosis Therapeutics (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Anti-Tuberculosis Therapeutics (Diagnosis) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Anti-Tuberculosis Therapeutics (Treatment) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Anti-Tuberculosis Therapeutics (Treatment) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Anti-Tuberculosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Anti-Tuberculosis Therapeutics (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Anti-Tuberculosis Therapeutics (Homecare) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Anti-Tuberculosis Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Anti-Tuberculosis Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: North America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: North America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: United States: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: United States: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Canada: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Canada: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Asia-Pacific: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Asia-Pacific: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: China: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: China: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Japan: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Japan: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: India: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: India: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: South Korea: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: South Korea: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Australia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Australia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Indonesia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Indonesia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Europe: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Europe: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Germany: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Germany: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: France: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: France: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: United Kingdom: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: United Kingdom: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Italy: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Italy: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Spain: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Spain: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Russia: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Russia: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Latin America: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Latin America: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Brazil: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Brazil: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Mexico: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Mexico: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Middle East and Africa: Anti-Tuberculosis Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 74: Middle East and Africa: Anti-Tuberculosis Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Global: Anti-Tuberculosis Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Anti-Tuberculosis Therapeutics Industry: Value Chain Analysis
  • Figure 77: Global: Anti-Tuberculosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Tuberculosis Therapeutics Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Disease Type (in Million US$), 2023-2028
  • Table 3: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Diagnosis and Treatment (in Million US$), 2023-2028
  • Table 4: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Anti-Tuberculosis Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Anti-Tuberculosis Therapeutics Market: Competitive Structure
  • Table 7: Global: Anti-Tuberculosis Therapeutics Market: Key Players
目次
Product Code: SR112023A7629

The global anti-tuberculosis therapeutics market size reached US$ 1,354.79 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,991.34 Million by 2028, exhibiting a growth rate (CAGR) of 6.70% during 2023-2028. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.

Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.

Anti-Tuberculosis Therapeutics Market Trends:

One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.

Disease Type Insights:

Active TB

Latent TB

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.

Diagnosis and Treatment Insights:

Diagnosis

Blood Tests

Imaging Tests

Sputum Tests

Others

Treatment

First-Line of Drugs

Isoniazid

Ethambutol

Rifampin

Others

Second-Line of Drugs

Thiacetazone

Paraaminosalicyclic Acid (PAS)

Others

Others

A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others

End User Insights:

Hospitals

Specialty Clinics

Homecare

Others

The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global anti-tuberculosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global anti-tuberculosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global anti-tuberculosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the disease type?
  • Which is the most attractive disease type in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on the diagnosis and treatment?
  • Which is the most attractive diagnosis and treatment in the anti-tuberculosis therapeutics market?
  • What is the breakup of the market based on end user?
  • Which is the most attractive end user in the anti-tuberculosis therapeutics market?
  • What is the competitive structure of the global anti-tuberculosis therapeutics market?
  • Who are the key players/companies in the global anti-tuberculosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Tuberculosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease Type

  • 6.1 Active TB
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Latent TB
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis and Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Tests
      • 7.1.2.2 Imaging Tests
      • 7.1.2.3 Sputum Tests
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 First-Line of Drugs
      • 7.2.2.1.1 Major Types
      • 7.2.2.1.1.1 Isoniazid
      • 7.2.2.1.1.2 Ethambutol
      • 7.2.2.1.1.3 Rifampin
      • 7.2.2.1.1.4 Others
      • 7.2.2.2 Second-Line of Drugs
      • 7.2.2.2.1 Major Types
      • 7.2.2.2.1.1 Thiacetazone
      • 7.2.2.2.1.2 Paraaminosalicyclic Acid (PAS)
      • 7.2.2.2.1.3 Others
      • 7.2.2.3 Others
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Homecare
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 F. Hoffmann-La Roche Ltd.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 SWOT Analysis
    • 14.3.2 Lannett Company Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Lupin Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Macleods Pharmaceuticals Limited
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Otsuka Pharmaceutical Co. Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.